Search company, investor...


Founded Year


About Phebra

Phebra develops, manufactures and supplies pharmaceuticals to meet the requirements of the hospital speciality pharmaceutical market.

Headquarters Location

19 Orion Road Lane Cove West

Sydney, New South Wales, 2066,


+61 (0) 2 9420 9199

Missing: Phebra's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Phebra's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Phebra News

Phebra Acquires Equity Stake In UK Specialty Hospital Pharma Company Flexipharm Austrading

Nov 3, 2021

Phebra Acquires Equity Stake In UK Specialty Hospital Pharma Company Flexipharm Austrading - Phebra takes part ownership of Flexipharm Austrading through share purchase Author: SYDNEY and BOURNE END, England, Nov. 3, 2021 /PRNewswire/ -- Leading Australian pharmaceutical group Phebra Holdings ('Phebra') is pleased to announce that it has completed a share purchase agreement with the UK hospital specialty pharmaceutical company Flexipharm Austrading Limited ('FAL'). Flexipharm Austrading, a privately-owned company founded in 2018 by experienced specialty pharma expert, Michael Clark, focuses on supplying UK hospitals with Better Critical Care Medicines. Flexipharm Austrading has an existing licence and distribution agreement with Phebra for the supply of products from Phebra's portfolio of critical care medicines; to date several products have been approved and successfully launched in the UK. Andre Vlok, Chief Executive Officer Phebra, said: "We are excited that Phebra has made this strategic investment in Flexipharm Austrading. This is a logical next step for Phebra, deepening a strong and successful collaboration built over the last 3 years. It strengthen Phebra's access to the key UK market which is very important for our current and future pipeline of critical care products. "Our partnership will allow us to leverage the existing infrastructure at FAL under the expert leadership of Michael and to advance our route to market in the UK and potentially, expand our international sales into wider, selected European markets." Michael Clark, Founder and Managing Director of Flexipharm Austrading, said: "I established the business with a goal to supply UK hospitals with Better Critical Care Medicines; Phebra had a portfolio of products that we believed offered advantages over existing products and together we have successfully launched these in the UK. But the job is only part-completed; I am delighted that Phebra is now a shareholder and look forward to deepening this relationship which is based around supplying hospitals with a focus on improved or novel versions of gold standard drugs and offering tangible and transparent value to the NHS, healthcare professionals and, independent hospitals." About Phebra Phebra is an Australian based specialty pharmaceutical group which develops, manufactures and markets critical medicines across the world. At Phebra, we create critical medicines that save and improve lives. About Flexipharm Austrading Flexipharm Austrading's vision is to become a UK-based specialty pharmaceutical company that is genuinely respected and trusted by NHS hospitals. It was founded in 2018 by Michael Clark, an experienced specialty pharmaceutical company founder and board director. Flexipharm Austrading has a singular focus on commercialising established molecules embedded in hospital use where there are concerns around security of ongoing supply; where the current presentation is not optimal for the needs of the NHS staff; and where the current presentations can contribute to medication errors. The Company has a deep understanding of the conditions where its medicines are used and builds enduring meaningful dialogue with the NHS staff involved in using these medicines. It works in partnership with Phebra Pty Ltd, an Australian pharmaceutical company developing and manufacturing injectable pharmaceutical products. For further information visit . View original content:

Phebra Frequently Asked Questions (FAQ)

  • When was Phebra founded?

    Phebra was founded in 1993.

  • Where is Phebra's headquarters?

    Phebra's headquarters is located at 19 Orion Road, Sydney.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.